FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories
This article was originally published in The Pink Sheet Daily
Executive Summary
Hikma must divest rights to three drugs under Roxane Labs deal as Federal Trade Commission aims to preserve as many as five competitors in some markets.
You may also be interested in...
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.
Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation
Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.
Oncopeptides’ Pepaxto Needs New Study To Identify Population That Will Benefit, FDA Panel Says
Advisory committee votes 14-2 that melflufen’s benefit-risk profile is unfavorable in the current accelerated approval indication for fifth-line treatment of multiple myeloma; panel rejects sponsor’s attempt to rely on post hoc analyses to 'carve out' a subpopulation that, it asserts, is responsible for negative overall survival trend in OCEAN confirmatory trial.